MA52629A - Agents inhibiteurs de la tyrosine kinase de bruton - Google Patents

Agents inhibiteurs de la tyrosine kinase de bruton

Info

Publication number
MA52629A
MA52629A MA052629A MA52629A MA52629A MA 52629 A MA52629 A MA 52629A MA 052629 A MA052629 A MA 052629A MA 52629 A MA52629 A MA 52629A MA 52629 A MA52629 A MA 52629A
Authority
MA
Morocco
Prior art keywords
tyrosine kinase
kinase inhibitors
bruton tyrosine
bruton
inhibitors
Prior art date
Application number
MA052629A
Other languages
English (en)
Inventor
Michael Dechantsreiter
Brian T Hopkins
Bin Ma
Isaac Marx
Marta Nevalainen
Robin Prince
Jürgen Schulz
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of MA52629A publication Critical patent/MA52629A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA052629A 2018-05-14 2019-05-13 Agents inhibiteurs de la tyrosine kinase de bruton MA52629A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862671053P 2018-05-14 2018-05-14

Publications (1)

Publication Number Publication Date
MA52629A true MA52629A (fr) 2021-03-24

Family

ID=67002348

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052629A MA52629A (fr) 2018-05-14 2019-05-13 Agents inhibiteurs de la tyrosine kinase de bruton

Country Status (9)

Country Link
US (1) US10899753B2 (fr)
EP (1) EP3793994B1 (fr)
JP (1) JP7359782B2 (fr)
AR (1) AR115085A1 (fr)
ES (1) ES2968222T3 (fr)
MA (1) MA52629A (fr)
TW (1) TW202016097A (fr)
UY (1) UY38233A (fr)
WO (1) WO2019222101A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53914A (fr) * 2018-10-15 2021-08-25 Biogen Ma Inc Polymorphes cristallins d'inhibiteurs de la tyrosine kinase de bruton
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
JP7646671B2 (ja) * 2019-12-23 2025-03-17 バイオジェン・エムエイ・インコーポレイテッド Btk阻害剤
CN112062691B (zh) * 2020-06-18 2022-12-09 中国农业科学院油料作物研究所 一种柠檬醛苯丁酸肟酯类化合物及其合成方法和应用
US20240216330A1 (en) 2021-04-02 2024-07-04 Biogen Ma Inc. Combination treatment methods of multiple sclerosis
EP4457225A4 (fr) 2021-12-30 2025-09-24 Beigene Switzerland Gmbh Dégradation de la tyrosine kinase de bruton (btk) par conjugaison d'inhibiteurs de btk avec un ligand de ligase e3 et procédés d'utilisation
JP7805983B2 (ja) 2022-03-22 2026-01-26 アッヴィ・インコーポレイテッド ブルトン型チロシンキナーゼを分解するためのピリミジン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US20150011751A1 (en) * 2012-03-09 2015-01-08 Carna Biosciences, Inc. Novel triazine derivative
EP3080122B1 (fr) 2013-12-11 2018-10-31 Biogen MA Inc. Composes biaryles utiles dans le traitement de maladies humaines en oncologie, neurologie et immunologie
SG11201604595VA (en) 2013-12-11 2016-07-28 Biogen Ma Inc Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
EP3307732A1 (fr) * 2015-06-10 2018-04-18 Biogen MA Inc. Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton

Also Published As

Publication number Publication date
US10899753B2 (en) 2021-01-26
UY38233A (es) 2019-12-31
US20190382394A1 (en) 2019-12-19
AR115085A1 (es) 2020-11-25
EP3793994B1 (fr) 2023-08-23
TW202016097A (zh) 2020-05-01
WO2019222101A1 (fr) 2019-11-21
JP2021523206A (ja) 2021-09-02
ES2968222T3 (es) 2024-05-08
EP3793994A1 (fr) 2021-03-24
JP7359782B2 (ja) 2023-10-11

Similar Documents

Publication Publication Date Title
EP3873477A4 (fr) Inhibiteurs de la kinase cycline-dépendante 7 (cdk7)
MA53921A (fr) Inhibiteurs de protéine tyrosine phosphatase
IL286462A (en) Protein tyrosine phosphatase inhibitors
EP3844151A4 (fr) Inhibiteurs de kras g12c
MA54543A (fr) Inhibiteurs de kif18a
MA54550A (fr) Inhibiteurs de kif18a
MA42623A (fr) Inhibiteurs de la tyrosine kinase de bruton
EP3414234A4 (fr) Inhibiteurs de la tyrosine kinase de bruton
EP3710439A4 (fr) Inhibiteurs de kras g12c
MA43162A (fr) Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton
EP3405192A4 (fr) Inhibiteurs de la tyrosine kinase de bruton
MA52629A (fr) Agents inhibiteurs de la tyrosine kinase de bruton
EP3740206A4 (fr) Inhibiteurs de la kinase cycline-dépendante 7 (cdk7)
MA42242A (fr) Inhibiteurs de la tyrosine kinase
MA52812A (fr) Inhibiteurs de sarm1
MA41350A (fr) Synthèse d'un inhibiteur de la tyrosine kinase de bruton
EP3902805A4 (fr) Inhibiteurs de kinase cycline-dépendants
MA52813A (fr) Inhibiteurs de sarm1
EP3804707A4 (fr) Inhibiteur de kinase
EP3817736A4 (fr) Inhibiteurs de pikfyve
EP3962908A4 (fr) Inhibiteurs hétérocycliques de tyrosine kinase
DK3609886T3 (da) Benzoazepinanaloger som inhiberingsmidler for bruton-tyrosinkinase
MA41827A (fr) Formes solvatées d'un inhibiteur de la tyrosine kinase de bruton
MA52809A (fr) Inhibiteurs de sarm1
ZA201906887B (en) Bruton's tyrosine kinase inhibitors